Autologous Bone Marrow and Peripheral Blood Stem Cell Transplantation in Multiple Myeloma

References

• Bergsagel D E, Sprague C C, Austin C, et al. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-phenylalanine mustard. Cancer Chemother Rep 1962; 21: 87–99
   PubMedGoogle Scholar
• Balaille R, Grenier J, Sany J. Beta-2-microglobulin in myeloma: Optimal use for staging, prognosis and treatment—A prospective study of 160 patients. Blood 1984; 63: 468–476
   PubMed Web of Science ®Google Scholar
• Boccadoro M, Marmont F, Tribalto M, et al. VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991; 9: 444–448
   PubMed Web of Science ®Google Scholar
• Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma—New biologic insights and advances in therapy. Blood 1989; 73: 865–879
   PubMed Web of Science ®Google Scholar
• Hoffman M, Tallman M S, Hakimian D, et al. 2-Chlorodeoxy-adenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 788–792
   PubMed Web of Science ®Google Scholar
• Redman J R, Cabanillas F, Velasques W S, et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790–794
   PubMed Web of Science ®Google Scholar
• Cassileth P A, Cheuvart B, Spiers A SD, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 1991; 9: 243–246
   PubMed Web of Science ®Google Scholar
• Barlogie B. Toward a cure for multiple myeloma?. N Engl J Med 1991; 325: 1304–1306
   PubMed Web of Science ®Google Scholar
• Jagannath S, Vesole D H, Glenn L, et al. Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666–1672
   PubMed Web of Science ®Google Scholar
• Vesole D H, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950–956
   PubMed Web of Science ®Google Scholar
• Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312–1322
   PubMed Web of Science ®Google Scholar
• Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–1356
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86–89
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos M A, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887–890
   PubMed Web of Science ®Google Scholar
• Hata H, Xiao H, Petrucci M T, Woodliff J, Chang R, Epstein J. Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood 1993; 81: 3357–3364
   PubMed Web of Science ®Google Scholar
• Epstein J, Barlogie B. Tumor resistance to chemotherapy associated with expression of the multidrug resistance phenotype. Cancer Bull 1989; 41: 41–44
   Google Scholar
• Alexanian R, Barlogie B, Dixon D. High dose glucocorticoid treatment for resistant multiple myeloma. Ann Intern Med 1986; 105: 8–11
   PubMed Web of Science ®Google Scholar
• McElwain T J, Powles R L. High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 1983; 1: 822–823
   Google Scholar
• Barlogie B, Hall R, Zander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298–1301
   PubMed Web of Science ®Google Scholar
• Barlogie B, Alexanian R, Dicke K, et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869–872
   PubMed Web of Science ®Google Scholar
• Fermand J P, Levy Y, Gerota J, et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cell autologous graft. Blood 1989; 73: 20–23
   PubMed Web of Science ®Google Scholar
• Henon P H, Beck G, Debecker A, et al. Autograft using peripheral blood stem cells collected after high dose melphalan in high risk myeloma. Br J Haematol 1988; 70: 254–255
   PubMed Web of Science ®Google Scholar
• Reiffers J, Marit G, Boiron J M. Autologous blood stem cell transplantation in high-risk multiple myeloma. Br J Haematol 1989; 72: 296–297
   PubMed Web of Science ®Google Scholar
• Altai M, Huguet M, Schiaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79: 1130–1136
   PubMed Web of Science ®Google Scholar
• Altai M, Harousseau J L, Stoppa A M, Solto J J, Fuzibet G, Rossi J F, Casassus P, Thyss A, Maisonneuve H, Facon T, Ifrah N, Paven C, Bataille R. High dose therapy in multiple myeloma: A prospective randomized study of the “Intergroupe Francais du Myeloma.”. Blood 1995; 86: 124a, (abslract)
   Google Scholar
• Harousseau J L, Milpied N, Laporle J P, et al. Double intensive therapy in high risk multiple myeloma. Blood 1992; 79: 2827–2833
   PubMed Web of Science ®Google Scholar
• Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759–763
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Alexanian R, Przepiorka D, et al. Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324–2328
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole D, Miller L, Cheson B, Bracy D, Tricot G. Total therapy (TT) for 202 newly diagnosed patients with multiple myeloma. Blood 1994; 84: 386a, (abstract)
   Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Dicke K A, et al. Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors. Blood 1990; 76: 1860–1866
   PubMed Web of Science ®Google Scholar
• Tricot G, Jagannath S, Vesole D H, Barlogie B. Relapse of multiple myeloma after autologous transplantation: Survival outcome after salvage therapy. Bone Marrow Transplant 1995; 16: 7–11
   PubMed Web of Science ®Google Scholar
• Vesole D H, Jagannath S, Tricot G, Siegel D, Desikan K R, Vaught L, Barlogie B. Efficacy and safety of high dose therapy with autotransplantation (AT) in multiple myeloma (MM) patients over age 60. Blood 1995; 86: 206a, (abstract)
   Google Scholar
• Govindarajan R, Flick J T, Tricot G, Vesole D, Jagannath S, Mattox S, Sawyer J, Barlogie B. Secondary myelodysplastic syndromes (MDS) in multiple myeloma (MM) after autotransplant (AT) are due to prolonged alkylating agent therapy prior to AT. Blood 1995; 86: 337a, (abstract)
   Google Scholar
• Tricot G, Barlogie B, Jagannath S, Vesole D, Naucke S, Tian E, Gazitt Y. Double autotransplants can induce molecular remissions (MCR) in newly diagnosed patients with multiple myeloma (MM). Blood 1995; 86: 969a, (abstract)
   Google Scholar
• Barlogie B, Crowley J, Jagannath S, Vesole D, Tricot G, Jacobson J, Salmon S. Superior outcome after early autotransplantation (AT) with “Total Therapy” (TT) compared to standard SWOG treatment (ST) for multiple myeloma (MM). Blood 1995; 86: 207a, (abstract)
   Web of Science ®Google Scholar
• Cuba S C, Jagannath S, Tricot G, Desikan K R, Siegel D, Barlogie B, Vesole D. CD34 peripheral blood stem cell (PBSC) mobilization, infusion and engraftment in patients with multiple myeloma (MM) over the age of 60. Blood 1995; 86: 948a, (abstract)
   Google Scholar
• Tricot G, Alberts D S, Roe D, Dorr R T, Vesole D H, Jagannath S, Barlogie B. High dose melphalan (MEL) and renal function in multiple myeloma (MM). Blood 1994; 84: 180a, (abstract)
   Web of Science ®Google Scholar
• Bjorkstrand B, Ljungman P, Bird J M, Samson D, Gahrton G. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant 1995; 15: 367–371
   PubMed Web of Science ®Google Scholar
• Cunningham D, Paz-Ares L, Gore M E, Malpas J, Hickish T, Nicolson M, Meldrum M, Viner C, Milan S, Selby P J, Norman A, Raymond J, Powles R. High-dose melphalan for multiple myeloma: Long-term follow-up data. J Clin Oncol 1994; 12: 764
   PubMed Web of Science ®Google Scholar
• Harousseau J L, Altai M, Divine M, Milpied N, Marit G, Leblond V, Stoppa A M, Bourhis J H, Caillot D, Boasson M, Abgrall J F, Facon T, Colombat P, Cahn J Y, Lamy T, Troussard X, Gratecos N, Pignon B, Auzanneau G. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant 1995; 15: 963
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos M A, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278–4282
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin R. Limited value of myeloablative therapy for late multiple myeloma. Blood 1994; 83: 512–516
   PubMed Web of Science ®Google Scholar
• Vesole D H, Tricot G, Jagannath S, Desikan K R, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B. Autotransplants in multiple myeloma: What have we learned?, (submitted)
   Google Scholar
• Barlogie B, Anderson K, Berenson J, Crowley J, Cunningham D, Gertz M, Henon P, Horowitz M, Jagannath S, Powles R, Reece D, Reiffers J, Salmon S, Tricot G, Vesole D. Transplants for multiple myeloma. Bone Marrow Transplant 1995; 15(Suppl 1)234–239
   Google Scholar
• Gianni A M, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580–584
   PubMed Web of Science ®Google Scholar
• Vesole D H, Jagannath S, Tricot G, Barlogie B. Intensive therapy with hematopoietic stem cell transplantation for the treatment of multiple myeloma. High-Dose Cancer Therapy, 2nd ed, J Armitage, J Vose. Williams & Wilkins, Baltimore 1995; 728–743
   Google Scholar
• Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–596
   PubMed Web of Science ®Google Scholar
• Desikan K R, Jagannath S, Vesole D, et al. Collection of peripheral blood stem cells (PBSC) in multiple myeloma (MM) following G-CSF with or without high-dose cyclophosphamide (HD-CTX). Blood 1995; 86: 1594
   Web of Science ®Google Scholar
• Horowitz M M, Gale R P, Sondel P M, Goldman J M, Kersey J, Kolb H.-J., Rimm A A, Ringden O, Rozman C, Speck B, Truitt R L, Zwaan F E, Bortin M M. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Drobyski W R, Keever C A, Roth M S, Koethe S, Hanson G, McFadden P, Gottschall J L, Ash R C, van Tuinen P, Horowitz M M, Flomenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310–2318
   PubMed Web of Science ®Google Scholar
• Tricot G, Vesole D H, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus myeloma effect: Proof of principle. Blood 1996; 87
   Web of Science ®Google Scholar
• Boranic M, Tonkovic I. Time pattern of the antileukemic effect of graft-versus-host reaction. Cancer Res 1971; 31: 1140
   PubMed Web of Science ®Google Scholar
• Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 322: 1430–1434
   PubMed Web of Science ®Google Scholar
• Browman G P, Bergsagel D, Sicheri D, O'Reilly S, Wilson K S, Rubin S, Belch A, Shustik C, Barr R, Walker I, James K, Zee B, Johnston D. Randomized trial of interferon maintenance in multiple myeloma: A study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995; 13: 2354–2360
   PubMed Web of Science ®Google Scholar
• The Nordic Myeloma Study Group. Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: A randomized, controlled trial. Ann Intern Med 1996; 124: 212–222
   PubMed Web of Science ®Google Scholar
• Kwak L W, Campbell M J, Czerwinski B S, Hart S, Miller R A, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1236–1237
   PubMedGoogle Scholar
• Kwak L W, Taub D D, Duffey P L, Bensinger W I, Bryant E M, Reynolds C W, Longo D L. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 1995; 345(8956)1016–1020
   PubMed Web of Science ®Google Scholar
• Billadeau D, Ahmann G, Greipp P, et al. Allele-specific polymerase chain reaction techniques for the detection and characterization of multiple myeloma. IV International Workshop on Multiple Myeloma, Rochester, Minnesota, October, 2–5, 1993; 35
   Google Scholar
• Bird J M, Samson D, Russel N H. Minimal residual disease after BMT for multiple myeloma. Blood 1993; 82: 199a
   Web of Science ®Google Scholar
• Brenner M K, Hill D R, Moen R C, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Tian E, Barlogie B, et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma following treatment with cyclophosphamide and GMCSF. Blood 1996; 87: 805–811
   PubMed Web of Science ®Google Scholar
• Sato N, Sawada K, Koizumi K, et al. In vitro expansion of human peripheral blood CD34+ cells. Blood 1993; 82: 3600–3609
   PubMed Web of Science ®Google Scholar
• Anderson K C, Andersen J, Soiffer R, et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 1993; 82: 2568–2576
   PubMed Web of Science ®Google Scholar
• Schiller G, Vescio R, Lee M, et al. Transplantation of autologous CD34-positive peripheral blood stem cells as treatment for multiple myeloma. Blood 1993; 82: 198a, (abstract)
   Web of Science ®Google Scholar
• Baum C M, Weissman I L, Tsukamoto A S, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 1992; 89: 2804–2808
   PubMed Web of Science ®Google Scholar
• Tricot G, Gazitt Y, Jagannath S, Vesole D, Reading C, Juttner C, Hoffman R, Barlogie B. CD34+Thy+Lin- peripheral blood stem cells (PBSC) effect timely trilineage engraftment in multiple myeloma (MM). Blood 1995; 86: 293a, (abstract)
   Google Scholar
• Hoover R G, Lary C, Page R, Travis P, Owens R, Flick J, Kornbluth J, Barlogie B. Autoregulatory circuits in myeloma: Tumor cell cytotoxicity mediated by soluble CD16. J Clin Invest 1995; 95: 241–247
   PubMed Web of Science ®Google Scholar
• Stevenson F K, Bell A J, Cusack R, Hamblin T J, Slade C J, Spellerberg M B, Stevenson G T. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 1991; 77: 1071–1079
   PubMed Web of Science ®Google Scholar
• Grossbard M L, Gribben J G, Freedman A S, Lambert J M, Kinsella J, Rabinowe S N, Eliseo L, Taylor J A, Blattler W A, Epstein C L, Nadler L M. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81: 2263–2271
   PubMed Web of Science ®Google Scholar
• Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: Biological and therapeutic implications. Cancer Res 1991; 51: 4505–4510
   PubMed Web of Science ®Google Scholar
• Cuthbert J A, Lipsky P E. Suppression of the proliferation of Ras-transformed cells by fluorome valonate, an inhibitor of mevalonate metabolism. Cancer Res 1995; 55: 1732–1740
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedi-chloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995; 55: 590–596
   PubMed Web of Science ®Google Scholar